Amgen is reportedly interested in BioCryst Pharmaceuticals, which operates in the rare-disease market, as a potential acquisition target.
1 report, 1 independent
Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amgen is reportedly interested in BioCryst Pharmaceuticals, which operates in the rare-disease market, as a potential acquisition target.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Amgen
American multinational biopharmaceutical company
-
BioCryst Pharmaceuticals
American pharmaceutical company
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
- Amgen and Gilead Sciences are two companies that compete within the biotech industry.
- Amgen Inc. trades on the NASDAQ stock exchange.
- Amgen and Merck are currently competing against each other in the market for investor capital.
- Biofrontera and AstraZeneca are being compared as healthcare companies for investment.
- Replimune Group received FDA accelerated approval, and Mestag Therapeutics appointed new board members, including Victor Sandor and Philip Astley-Sparke.